Literature DB >> 8520768

Impaired natural immunity to pneumolysin during human immunodeficiency virus infection in the United States and Africa.

B M Amdahl1, J B Rubins, C L Daley, C F Gilks, P C Hopewell, E N Janoff.   

Abstract

Human immunodeficiency virus (HIV) infection is associated with a significantly increased incidence of pneumococcal pneumonia and concomitant bacteremia. We hypothesized that the predisposition of HIV-infected patients to invasive pneumococcal infection may be related, in part, to an impaired immune response to the pneumococcal antigen pneumolysin (PLY) because PLY facilitates bacterial invasion. We measured serum anti-PLY antibodies in two separate populations of HIV-infected and HIV-seronegative controls, using both an enzyme-linked immunosorbent assay method and a functional assay of antibody inhibition of PLY-induced hemolysis and cytotoxicity. HIV-infected patients in the United States had significantly lower titers of anti-PLY antibodies by both methods than did seronegative control subjects. Moreover, HIV-infected patients in Kenya who later developed pneumococcal bacteremia also had significantly lower anti-PLY antibody levels at baseline compared with seronegative control subjects. We conclude that lower baseline levels of antibodies to PLY are associated with the higher incidence of bacteremic pneumococcal infections among HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8520768     DOI: 10.1164/ajrccm.152.6.8520768

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  8 in total

1.  A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae.

Authors:  Philippe Denoël; Mario T Philipp; Lara Doyle; Dale Martin; Georges Carletti; Jan T Poolman
Journal:  Vaccine       Date:  2011-05-30       Impact factor: 3.641

2.  Age-specific immunoglobulin g (IgG) and IgA to pneumococcal protein antigens in a population in coastal kenya.

Authors:  Catherine Laine; Tabitha Mwangi; Claudette M Thompson; Jacktone Obiero; Marc Lipsitch; J Anthony G Scott
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

Review 3.  Rapid diagnosis of pneumococcal pneumonia among HIV-infected adults with urine antigen detection.

Authors:  David R Boulware; Charles L Daley; Cynthia Merrifield; Philip C Hopewell; Edward N Janoff
Journal:  J Infect       Date:  2007-08-10       Impact factor: 6.072

4.  Impaired CD4 T cell memory response to Streptococcus pneumoniae precedes CD4 T cell depletion in HIV-infected Malawian adults.

Authors:  Sarah J Glennie; Enoch Sepako; David Mzinza; Visopo Harawa; David J C Miles; Kondwani C Jambo; Stephen B Gordon; Neil A Williams; Robert S Heyderman
Journal:  PLoS One       Date:  2011-09-27       Impact factor: 3.240

5.  Incomplete recovery of pneumococcal CD4 T cell immunity after initiation of antiretroviral therapy in HIV-infected malawian adults.

Authors:  Enoch Sepako; Sarah J Glennie; Kondwani C Jambo; David Mzinza; Oluwadamilola H Iwajomo; Dominic Banda; Joep J van Oosterhout; Neil A Williams; Stephen B Gordon; Robert S Heyderman
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

6.  Coexpression Analysis of Transcriptome on AIDS and Other Human Disease Pathways by Canonical Correlation Analysis.

Authors:  Yahong Chen; Jinjin Yuan; Xianlin Han; Xiaolong Liu; Xiao Han; Hanhui Ye
Journal:  Int J Genomics       Date:  2017-06-14       Impact factor: 2.326

7.  Effect of recurrent invasive pneumococcal disease on serum anti-pneumolysin IgG titres in HIV infected adults.

Authors:  Onajite M Etuwewe; Natalie Swann; Susan Hollingshead; Helen Tolmie; Ed E Zijlstra; Brian Faragher; Neil French; Stephen B Gordon
Journal:  Vaccine       Date:  2009-05-03       Impact factor: 3.641

8.  Increased IgG but normal IgA anti-pneumococcal protein antibodies in lung of HIV-infected adults.

Authors:  Andrea M Collins; Sherouk El Batrawy; Stephen B Gordon; Daniela M Ferreira
Journal:  Vaccine       Date:  2013-05-10       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.